A DNA strand-based fluorescent probe was developed for the direct simultaneous detection of small cell lung cancers' tumor markers NSE and ProGRP. The probe offers stability, simplicity, and rapid response, making it highly promising for application in clinical serum samples' diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d4cc06230b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Precise detection of NSE and ProGRP with nanoprobes for early diagnosis of small cell lung cancer.
Chem Commun (Camb)
January 2025
College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, Jinan 250014, P. R. China.
A DNA strand-based fluorescent probe was developed for the direct simultaneous detection of small cell lung cancers' tumor markers NSE and ProGRP. The probe offers stability, simplicity, and rapid response, making it highly promising for application in clinical serum samples' diagnosis.
View Article and Find Full Text PDFThe Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.
Ann Clin Lab Sci
November 2024
Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan, China
Objective: Urinary proteins are effective tumor biomarkers. Human epididymis protein 4 (HE4), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), cytokeratin-19 fragment 21-1(CYFRA 21-1), and neuron-specific enolase (NSE) in serum, were proposed as tumor biomarkers of lung cancer. Our aim was to identify the urine protein biomarkers that can distinguish patients with lung cancer from healthy individuals and/or patients with benign lung disease with a high level of sensitivity and specificity.
View Article and Find Full Text PDFFirst-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.
Front Immunol
January 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.
Case Presentation: We describe a 69-year-old AIDS patient who initially presented with a fused, enlarged lymph node on the right clavicle and mild, unexplained pain under the right axilla that worsened with severe coughing episodes.
Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.
Clin Chim Acta
January 2025
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address:
Article Synopsis
- The study investigated the potential of the abnormal glycan structure Siaα-2,6Gal for diagnosing lung cancer early and differentiating it from other conditions.
- Clinical data and serum samples were analyzed from 730 lung cancer patients and 120 healthy individuals, measuring various serum markers including Siaα-2,6Gal and traditional tumor markers.
- Results showed that Siaα-2,6Gal levels were significantly higher in lung cancer patients, especially in early-stage cases, indicating it may serve as a more effective biomarker than traditional tests for diagnosing lung cancer.*
The ratio of lymph node eluate/serum cytokeratin 21-1 is a potential predictor of lymph node metastasis in lung adenocarcinoma.
J Thorac Dis
September 2024
Department of Pathogenesis and Immunology, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- Lymph node metastasis (LNM) is crucial for assessing lung cancer prognosis, prompting a study on using lymph node eluate biomarkers to improve LNM diagnostics in lung adenocarcinoma (LUAD).
- A study was conducted with 48 LUAD patients suspected of having LNM, analyzing specific biomarkers (CEA, CYFRA21-1, NSE, ProGRP) in both lymph node eluate and serum samples to distinguish between LNM and non-LNM cases.
- Results showed that the ratio of CYFRA21-1 in lymph node eluate to serum was the most effective in diagnosing LNM, achieving high sensitivity (92.3%) and specificity (92.9%), suggesting it could be
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!